Janssen Pharmaceutica NV has identified 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, viral hepatitis, diabetes, immunological, inflammatory, neurological, cardiovascular and metabolic disorders.